CORONA Project

CORONA (COvid19 Registry of Off-label & New Agents) Project

Director/Lead Investigator: David Fajgenbaum, MD, MBA, MSc

About the Project

The CDCN launched the CORONA Project in March 2020 to identify and track all treatments reported to be used for COVID-19 in an open-source data repository. The CORONA team has reviewed 29,353 papers and extracted 2,399 papers on 590 treatments administered to 437,936 patients with COVID-19, and in continuing to help researchers to prioritize treatments for clinical trials and inform patient care.

All data is made available via our Tableau-based CORONA Viewer that has recorded over 23,000 views to date and counts staff at Google Health, HHS, FDA, and NIH among regular users.  You can visit the CORONA database viewer built and managed by Matt Chadsey, owner of Nonlinear Ventures below. We have also written some high level articles about the project and its findings in our CORONA INSIGHTS blog. 



The overarching goal of the CORONA project is to advance effective treatments for COVID-19 by highlighting the most promising treatments to pursue, informing optimal clinical trial study design (sample size, target subpopulations), and determining if a drug should move forward to widespread clinical use. While there have been several notable failures in drug repurposing for COVID-19, a handful of drugs, including dexamethasone, heparin and baricitinib, have likely helped save thousands of lives and more treatments are urgently needed for newly diagnosed and soon to- be-diagnosed COVID-19 patients while vaccinations are underway and potential SARS-CoV-2 variants emerge. We’ve identified ~10 additional promising medications that, in collaboration with researchers at the FDA, NIH and elsewhere, we’re hoping to move into randomized control trials.

To further pursue our goal by the end of 2021, we will be expanding our work to also integrate pre-clinical and randomized controlled trial data. We believe that this expanded focus will allow us to more quickly advance promising treatments to clinical care that are supported by broader research findings.  

Key Milestones

We’re hiring:

  • Managing Director – more information here.
  • Bioinformatician/Computational Biologist – more information here.
  • Research Coordinator – more information here.


We are grateful to our current and past team members who have taken on this urgent need:

Dr. David Fajgenbaum, CSTL Director

Johnson Khor, Former CSTL Coordinator and COVID19 Project Lead

Sheila Pierson, CSTL Clinical Research Director

Dr. Ruth-Anne Langan, Former Penn Immunology PhD Student and COVID19 Data Analyst

Alek Gorzewski, ACCELERATE Data Analyst and COVID19 Data Analyst

Avery Tamakloe, ACCELERATE Data Analyst and COVID19 Data Analyst

Victoria Powers, ACCELERATE Data Analyst and COVID19 Data Analyst

Rozena Rasheed, Former BioBank Coordinator

Mileva Repasky, CDCN Chief Patient and Development Officer and COVID19 Data Analyst

Joseph Kakkis, UPenn BA Candidate and COVID19 Data Analyst

Alexis Phillips, Former CDCN Biomedical Leadership Fellow, UPenn Med student

Ania Korsunska, CDCN Biomedical Leadership Fellow, Syracuse University PhD Candidate

Our phase I team of data analysts:

Alex Beschloss, Madison McCarthy, Anne Taylor, Erin Napier, Lia Keyser, Dr. Duncan Mackay, Alex Beschloss, Anna Wing,  Ashwin Amurthur,  Beatrice Go,  Casey Kim,  James Germi,  Joanna Jiang,  Laura Miyarnes,  Michael Mayer,  Philip Angelides,  Sarah Frankl,  Vivek Nimgaonkar, Steve Bambury, Bruna Martins, Megan Fisher, Karen Gunderson, Cornelia Keyser,  and Nick Goodyear.

And our Phase II team members who have continued this important work:

Abhishek Goel, Aura Enache, Ariana Weiss, Akash Hemanth, Alana Rush, Alex BEschloss, Allie Liebmann, Ambika Menon, Anna Sloan, Biliana Veleva Rotse, Anna Butkiewicz, Anne Taylor, Annika Balakrishnan, Abhi Rao, Ariel Gordon, Ayelet Rubenstein, Bruna Martins, Brent Flanders, David Bright, Casey Alsumairi, Cheng Cheng, Christopher Gaeta, Christopher Reynolds, Claire Exaus, Josh Deffenbaugh, Dave Shanmugasundaram, Debra Kuykendall, Denise Wynett, Derek Ansel, Dorothy Kenny, Ekaanth Sravan, Elena Lazarus, Evaggelia Nassis, Florence Porterfield, Francisco Delgado, Gary Gravina, Hannah Miller, Dr. Noel Rodriguez, Hasan Saifee, Kate Chang, Helen Eisenach, HEather Farley, Henry Reinstein, Hadis Williams, Jayson Wisk, Jenna Pacheco, Jiwoo Kim, Josh Lefkowitz, Josh Qian, Karen Gunderson, Karin Kent, Kevin Freiert, Karen Garzon, KiBoem Kwon, Kim Firn, Kristen Stegeland, Kyra Taub, Lindsey Muratore, Lisa Stewart, Lou Scarmoutzos, Maggie Reilly, Shan Mukujina, Monica Mayorga, Meggie Goodridge, Meryt Hanna, Mi Zhang, Miriam Gracia, Mithuun Kanapathipillai, Matt Pepper, Margaret Sorenson, Morgan Wiese, My Ngyuen, Nancy Bates, Paul Niklewski, Nicole Hinson, Omar El Sayed, Philip Rybcznski, Pearl Joslyn, Prithvi Parthasarathy, Rebecca Morse, Raquel Gindi, Sarah Bates, Debra D, Edward Shadiack, Shenqin Yao, Katelyn Stebbins, Suhina Kanapathipillai, Sarah VanFleet, Sarah Weinshel, Tarra Shingler, Timothy Adesanya, Ty Demint, Trisha Parayil, Theresa Ruscitti

Our Partners:

Doctor Evidence’s (DRE) platform enables researchers to identify and discover evidence for analysis to generate actionable data insights far beyond human capabilities. The recent Coronavirus pandemic has shown the world the ever-increasing need to process voluminous amounts of data in real-time.  DRE is happy to support Dr. Fajgenbaum and his team’s vision for finding a COVID-19 cure through a systematic literature review. To learn more about this collaboration, check out this press release in Business Wire.  


Nonlinear Ventures helps communities and organizations leverage best practices in systems thinking, portfolio management, economic valuation, and data visualization to make better investments in communities and the environment. Matt Chadsey, the founder of Nonlinear Ventures,  is excited to support the work of CDCN and help make its innovative research accessible worldwide!


Manifold is a digital health discovery and development partner for leading life science companies, academic institutions, and non-profit organizations. Their partnerships are grounded in multi-disciplinary collaboration between biomedical scientists and computer scientists & engineers to realize patient impact. Manifold appreciates the opportunity to collaborate with Dr. Fajgenbaum and his team to identify medication candidates which could be repurposed to treat COVID-19 and to prioritize them for clinical trials.


Please email if you are interested in contributing to, or collaborating on this project. 

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left